TY - JOUR
T1 - The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC
AU - Perna, Marco
AU - Scotti, Vieri
AU - Ciammella, Patrizia
AU - Borghetti, Paolo
AU - D'angelo, Elisa
AU - Levra, Niccolò Giaj
AU - Fozza, Alessandra
AU - Mariotti, Matteo
AU - Salvestrini, Viola
AU - Bertolini, Federica
AU - Vagge, Stefano
AU - Taraborrelli, Maria
AU - Falcinelli, Lorenzo
AU - Taddeo, Alessandra
AU - Rossi, Roberto
AU - Costantino, Gianluca
AU - Frassinelli, Luca
AU - Filippi, Andrea Riccardo
AU - Greco, Carlo
AU - Franceschini, Davide
AU - Genovesi, Domenico
AU - Lohr, Frank
AU - Magrini, Stefano Maria
AU - Alongi, Filippo
AU - Livi, Lorenzo
AU - Bruni, Alessio
N1 - Publisher Copyright:
© 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction: In this observational, retrospective, multicenter study, we aimed to assess the safety of the combination of local metastasis-directed radiotherapy (RT) and immunotherapy (IT) in a cohort of advanced non–small-cell lung cancer (aNSCLC) patients. Material and Methods: We collected clinical data of aNSCLC patients who received concomitant RT and anti-PD-1/PD-L1 inhibitors in seven Italian centers from September 2015 to June 2019. Concomitant RT was defined as delivered ≤4 weeks before or after the first or last administration of immunotherapy, or within two consecutive cycles of ICI. All adverse events apparently related to RT and/or IT were graded according to the Common Terminology Criteria for Adverse Events, version 4.0, and reported in terms of incidence and severity as immune related or RT related, or combined. Results: We analyzed the clinical charts of 187 patients. Median follow-up time was 23 months, and median overall survival was 16.5 months (range, 3-162). Thirteen patients developed pure RT-related side effects, and 43 patients (23.9%) developed immune-related side effects. No additive toxic effects were observed. A case of grade 5 pulmonary toxicity was recorded as a possible consequence of a combined effect. Conclusion: This analysis suggests that the combination of concomitant RT and anti-PD-1/PD-L1 agents is safe, and the two toxicity profiles are independent. This study aimed to evaluate the tolerability of the combination of radiotherapy and immunotherapy for patients with advanced lung cancer. We retrospectively analyzed data for 187 patients who received the combined treatment in seven Italian centers from September 2015 to June 2019. After a median follow-up of 23 months, the majority of patients recovered from the adverse events; one patient experienced grade 5 lung toxicity. Our analysis indicates that the combination of immunotherapy and radiotherapy.
AB - Introduction: In this observational, retrospective, multicenter study, we aimed to assess the safety of the combination of local metastasis-directed radiotherapy (RT) and immunotherapy (IT) in a cohort of advanced non–small-cell lung cancer (aNSCLC) patients. Material and Methods: We collected clinical data of aNSCLC patients who received concomitant RT and anti-PD-1/PD-L1 inhibitors in seven Italian centers from September 2015 to June 2019. Concomitant RT was defined as delivered ≤4 weeks before or after the first or last administration of immunotherapy, or within two consecutive cycles of ICI. All adverse events apparently related to RT and/or IT were graded according to the Common Terminology Criteria for Adverse Events, version 4.0, and reported in terms of incidence and severity as immune related or RT related, or combined. Results: We analyzed the clinical charts of 187 patients. Median follow-up time was 23 months, and median overall survival was 16.5 months (range, 3-162). Thirteen patients developed pure RT-related side effects, and 43 patients (23.9%) developed immune-related side effects. No additive toxic effects were observed. A case of grade 5 pulmonary toxicity was recorded as a possible consequence of a combined effect. Conclusion: This analysis suggests that the combination of concomitant RT and anti-PD-1/PD-L1 agents is safe, and the two toxicity profiles are independent. This study aimed to evaluate the tolerability of the combination of radiotherapy and immunotherapy for patients with advanced lung cancer. We retrospectively analyzed data for 187 patients who received the combined treatment in seven Italian centers from September 2015 to June 2019. After a median follow-up of 23 months, the majority of patients recovered from the adverse events; one patient experienced grade 5 lung toxicity. Our analysis indicates that the combination of immunotherapy and radiotherapy.
KW - Advanced NSCLC
KW - Concomitant treatment
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85102996352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102996352&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2021.02.005
DO - 10.1016/j.cllc.2021.02.005
M3 - Article
AN - SCOPUS:85102996352
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
ER -